{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT03539536","nct_id":"NCT03539536","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03539536. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Telisotuzumab vedotin administered via intravenous (IV) infusion every 14 days.","label":"Telisotuzumab vedotin","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-08","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":270,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Telisotuzumab vedotin","type":"DRUG"}],"last_update":"2025-11-05","lead_sponsor":"AbbVie","official_title":"Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Response Rate (ORR) (Stage 1 and Stage 2)","timeFrame":"Up to approximately 3 years"},{"measure":"Number of Participants with Adverse Events (Alternate dose cohort)","timeFrame":"Up to approximately 3 years"}],"references":[{"citation":"Girard N, Goldman J, Lu S, Bar J, Horinouchi H, Daaboul N, Liu C, Cicin I, Katgi N, Zer A, Ciuleanu T, Reinmuth N, Planchard D, Lee SH, Mansfield AS, Moskovitz M, Baijal S, Baik C, Hrom JS, Heist RS, Yazici O, Verma M, Uema D, Patel S, Xia S, Ratajczak C, Camidge DR. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial. JTO Clin Res Rep. 2026 Mar 16;7(7):100988. doi: 10.1016/j.jtocrr.2026.100988. eCollection 2026 Jul.","pmid":"42368479","type":"DERIVED"},{"citation":"Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. J Clin Oncol. 2024 Sep 1;42(25):3000-3011. doi: 10.1200/JCO.24.00720. Epub 2024 Jun 6.","pmid":"38843488","type":"DERIVED"}],"start_date":{"date":"2018-10-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03539536"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03539536"}